GlassScriptPhysician profile
Tariq Sabir
NPI 1073526778
$4,015.03
in general payments reported to CMS, 2019-2025
32 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,262 · 2020: $318 · 2021: $222 · 2022: $28.38 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,771.75 | 2019 | |
| Janssen Biotech, INC. | $187.14 | 2019-2022 | |
| Amgen INC. | $110.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $103.78 | 2019-2025 | Keytruda, Keytruda Qlex |
| Foundation Medicine, INC. | $103.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $77.16 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $71.49 | 2019-2020 | |
| Tactile Systems Technology INC | $62.54 | 2025 | Flexitouch Plus, Nimbl |
| Pfizer INC. | $49.81 | 2019-2020 | |
| Tempus Ai, INC | $45.38 | 2025 | Xt Cdx |
| Eisai INC. | $42.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.68 | 2019 | |
| Glaxosmithkline, LLC. | $25.85 | 2025 | Blenrep |
| Gilead Sciences, INC. | $24.62 | 2019-2021 | |
| Beigene USA, INC. | $24.36 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.00 | 2020 | |
| Daiichi Sankyo INC. | $21.73 | 2021 | |
| Genzyme Corporation | $20.46 | 2021 | |
| Genentech USA, INC. | $20.06 | 2021 | |
| Seagen INC. | $19.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.02 | 2019 | |
| Astellas Pharma US INC | $17.56 | 2020 | |
| Amicus Therapeutics, INC. | $17.46 | 2020 | |
| Aveo Pharmaceuticals, INC. | $16.52 | 2025 | |
| Lilly USA, LLC | $16.16 | 2019 | |
| Array Biopharma INC | $15.39 | 2019 | |
| Kyowa Kirin, INC. | $14.99 | 2019 | |
| Myovant Sciences INC. | $14.59 | 2021 | |
| Exelixis INC. | $14.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.84 | 2020 | |
| Emd Serono, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Sabir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.